Umecrine Cognition has presented additional results in the phase IIa study, conducted in patients with cirrhosis and evidence of cognitive impairment in line with hepatic encephalopathy (HE). Redeye is optimistic that the data merits further development with golexanolone, but it is essential to learn about the path forward and have funding in place.